Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780119 | 1.00 | CASP3 (0.55) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| SCHEMBL4782347 | 1.00 | CASP3 (0.55) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| SCHEMBL13919613 | 0.88 | POLB (0.51) | CASP3L3MBTL1ALDH1A1MAPTNPSR1 | |
| SCHEMBL7614758 | 0.86 | GLS (0.55) | CASP3TDP1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL1529481 | 0.83 | EPHX1 (0.53) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| SCHEMBL1529483 | 0.83 | EPHX1 (0.53) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| SCHEMBL2370243 | 0.83 | EPHX1 (0.53) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1529614 | 0.82 | EPHX1 (0.52) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4778820 | 0.82 | EPHX1 (0.52) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29574342 | 0.82 | EPHX1 (0.52) | CASP3TDP1L3MBTL1EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | CASP3 600/4885TDP1 2015/4885L3MBTL1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.